Treating Residual HER2+ Disease After Neoadjuvant TCHP Jame Abraham, MD April 15, 2026

https://www.medscape.com/viewarticle/treating-residual-her2-disease-after-neoadjuvant-tchp-2026a1000agq Recently, I saw a 45-year-old patient who presented with a palpable left breast mass. The imaging showed a 5.6-cm mass, with multiple ipsilateral axillary lymph nodes present. The biopsy showed a poorly differentiated tumor, invasive ductal cancer, estrogen-receptor (ER)/progesterone-receptor (PR) negative, HER2-positive, 3+ with immunohistochemistry, and the biopsy of the axillary lymph nodes were also positive.